Jhonatan R. Mejia

Jhonatan R. Mejia

Auto-generated profile, based on publicly available information

Jhonatan R. Mejia

Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2019 in Diabetic Medicine
Verified
Journal Article
Open access
PDF file
RCRodrigo M Carrillo-Larco
Rodrigo M Carrillo-Larco
DAD. J. Aparcana‐Granda
D. J. Aparcana‐Granda
JMJ. R. Mejia
J. R. Mejia
NBN. C. Barengo
N. C. Barengo
ABAntonio Bernabe-Ortiz
Antonio Bernabe-Ortiz
Aim: To summarize the evidence on diabetes risk scores for Latin American populations.Methods: A systematic review was conducted (CRD42019122306) looking for diagnostic and prognostic models for type 2 diabetes mellitus among randomly selected adults in Latin America. Five databases (LILACS, Scopus, MEDLINE, Embase and Global Health) were searched. type 2 diabetes mellitus was defined using at least one blood biomarker and the reports needed to include information on the development and/or validation of a multivariable regression model. Risk of bias was assessed using the PROBAST guidelines.Results: Of the 1500 reports identified, 11 were studied in detail and five were included in the qualitative analysis. Two reports were from Mexico, two from Peru and one from Brazil. The number of diabetes cases varied from 48 to 207 in the derivations models, and between 29 and 582 in the validation models. The most common predictors were age, waist circumference and family history of diabetes, and only one study used oral glucose tolerance test as the outcome. The discrimination performance across studies was ~ 70% (range: 66–72%) as per the area under the receiving‐operator curve, the highest metric was always the negative predictive value. Sensitivity was always higher than specificity.Conclusion: There is no evidence to support the use of one risk score throughout Latin America. The development, validation and implementation of risk scores should be a research and public health priority in Latin America to improve type 2 diabetes mellitus screening and prevention.

12 October 2021 in Reproductive Health
Verified
Journal Article
Open access
PDF file
JMJhonatan R. Mejia
Jhonatan R. Mejia
ÁQÁngel J. Quincho-Estares
Ángel J. Quincho-Estares
AFAsstrid J. Flores-Rondon
Asstrid J. Flores-Rondon
GRGiancarlo Reyes-Beltran
Giancarlo Reyes-Beltran
IAIrene L. Arias-Sulca
Irene L. Arias-Sulca
CTCarlos J. Toro-Huamanchumo
Carlos J. Toro-Huamanchumo
Background: Adolescent pregnancy carries a high risk of severe health issues for both the mother and the newborn. Worldwide, 21 million adolescents give birth every year, with high percentages in Latin America. Most of the risk factors are met in indigenous communities, which is an underrepresented and poorly studied population. We aimed to assess the determinants of adolescent pregnancy in indigenous communities from the Peruvian central jungle. Methods: Through a case–control study, female adolescents aged 13 to 19 years old from seven indigenous communities of the Peruvian central jungle were interviewed. Adolescents with (cases) and with no (controls) pregnancy history, such as current pregnancy, children and abortion, fulfilled our eligible criteria. Our instrument explored: sociodemographic, adolescent and family characteristics, as well as perceptions of adolescent pregnancy. We performed a penalized maximum likelihood logistic regression analysis to obtain Odds Ratios (OR) and their 95% confidence intervals (95% CI). Results: We enrolled 34 cases and 107 controls. Overall, 53.9% were 15 to 19 years old. We found a significant association of being 15–19 years old (OR = 6.88, 95% CI 2.38–19.86, p < 0.0001) and an elementary school level of instruction (OR = 5.59, 95% CI 1.95–16.06, p = 0.001) with the risk of adolescent pregnancy. A marginal statistical significance between having five to six siblings and adolescent pregnancy was also reported (OR = 2.70, 95% CI 0.85–8.61, p = 0.094). Furthermore, adolescents with sexual and reproductive health communication with parents had a lower risk of adolescent pregnancy (OR = 0.17, 95% CI 0.06–0.47, p = 0.001). Conclusion: Our results suggest that public health and educational efforts should be age-specific focused within indigenous communities of the Peruvian central jungle, encouraging parents to talk about sexual and reproductive health topics with adolescents.

31 March 2023 in Revista Peruana de Medicina Experimental Y Salud Pública
Verified
Journal Article
Open access
PDF file
MLMedalit Luna-Vilchez
Medalit Luna-Vilchez
JMJhonatan R. Mejia
Jhonatan R. Mejia
ZOZhamanda N. Ortiz-Benique
Zhamanda N. Ortiz-Benique
MSMitsi Santiago-Abal
Mitsi Santiago-Abal
ATAlvaro Taype-Rondan
Alvaro Taype-Rondan
This study aimed to describe the use of medication in pediatric patients with COVID-19 hospitalized at the National Children’s Health Institute - San Borja (INSN-SB) in Lima, Peru, between March 2020 and March 2022. Therefore, we conducted a descriptive, observational study to evaluate the use of six medications: corticosteroids, ceftriaxone, azithromycin, immunoglobulin, hydroxychloroquine, and ivermectin. We compared the results among subpopulations defined according to the COVID-19 pandemic waves. We included 421 pediatric patients. Corticosteroids were prescribed to 40.4%, ceftriaxone to 35.6%, azithromycin to 12.1%, immunoglobulin to 3.6%, hydroxychloroquine to 2.4%, and ivermectin to 0.5% of the patients. The use of ceftriaxone and azithromycin was less frequent during the third wave. Hydroxychloroquine was used almost exclusively during the first wave. Only patients with pediatric multisystem inflammatory syndrome used immunoglobulin. Overall, the prescription of the evaluated medications decreased during the third wave.

30 June 2016 in ACTA MEDICA PERUANA
Verified
Journal Article
Open access
PDF file
RMRaul Montalvo
Raul Montalvo
JMJhonatan Mejía
Jhonatan Mejía
PRPercy Ramírez
Percy Ramírez
EREder Rojas
Eder Rojas
HSHenry Serpa
Henry Serpa
FQFrank Quispe
Frank Quispe
Objetivo: Evaluar la mortalidad en pacientes con infección por VIH/SIDA que reciben tratamiento antirretroviral (TAR) en un hospital público de Perú. Materiales y métodos: Se realizó un estudio observacional de cohorte retrospectivo de los pacientes con diagnóstico de infección por VIH/SIDA que recibieron tratamiento antirretroviral. Resultados: De 428 pacientes estudiados, la media de edad fue 37 años y la media del recuento de CD4 al inicio del TAR en el grupo de fallecidos fue 87,2 cels/uL frente a 153,2 cels/uL en el grupo de vivos, fallecieron 66 pacientes (15,4%) después de iniciar TAR. La mayoría (48,5%) de estos pacientes tenían recuento de CD4 menor de 200 cel/uL, 59,1% desarrollaron infección oportunista y 16,7% cambiaron de esquema antirretroviral en algún momento del TAR. La mortalidad durante los primeros 3 meses de TAR fue 32,6%; el análisis con múltiples variables se encontró asociación con tener CD4 mayor de 100 cel/mL (HR:0,57; IC95%: 0,29-1,11), la presencia de infección oportunista (HR: 1,1; IC95% 1,06-1,16) y tener una alta carga viral (HR 1,17; IC95%:1,07-1,48). La probabilidad de sobrevida de los pacientes con CD4 menor de 100 cel/mL a los 8 años en TAR es 68%. Conclusiones: El mayor número de muertes de los pacientes con infección por VIH/SIDA ocurre durante los tres primeros meses de TAR y está asociado a un diagnóstico tardío (alta carga viral, bajo CD4 y presencia de enfermedades oportunistas). Sugerimos la implementación de terapia supervisada durante los primeros meses de TAR en pacientes con CD4 menor de 100 cel/mL, para identificar en forma temprana las infecciones oportunistas.


23 June 2025 in Revista Peruana de Medicina Experimental Y Salud Pública
Verified
Journal Article
Open access
PDF file
Ariel BardachAriel Bardach
Ariel Bardach
AAAndrea Alcaraz
Andrea Alcaraz
JMJhonatan R. Mejia
Jhonatan R. Mejia
EEEspinola Espinola
Espinola Espinola
ELElena Lazo
Elena Lazo
APAndrés Pichon-Riviere
Andrés Pichon-Riviere
Objectives. To estimate the economic burden and disease burden associated with tobacco use in Peru and the projected effect of strengthening specific tobacco control measures. Materials and methods. We used a Markov microsimulation model to assess smoking-attributable mortality, disease events, economic costs, and projected benefits over ten years, considering the implementation of measures such as plain packaging, full enforcement of smoke-free laws, a complete ban on tobacco advertising, promotion, and sponsorship, and increased cigarette taxes. Results. Each year in Peru, approximately 22,350 deaths and 126,000 disease events are attributable to tobacco use, accounting for 19% of all deaths from heart disease, 18% of deaths from stroke, and 515,768 years of life lost. In addition, approximately 1.28% of gross domestic product is lost annually due to smoking. Over ten years, the implementation of plain packaging could prevent 6,218 deaths, 31,700 events, and save 576 million USD. Full compliance with smoke-free places would prevent 4,982 deaths, 25,400 events, and save 461 million USD. Banning advertising, promotion, and sponsorship could prevent 8,767 deaths, 44,700 events, and save 812 million USD. Increasing cigarette prices by 50% could prevent 20,400 deaths, 658,400 healthy life years lost, and an economic benefit of more than 3.3 billion USD. Conclusions. The economic and disease burden of tobacco use in Peru is significant. Greater efforts to control tobacco would significantly reduce this burden.